Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Research article

Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial

Orlando P. da Silva, David C. Knoppert, Michelle M. Angelini and Penelope A. Forret
CMAJ January 09, 2001 164 (1) 17-21;
Orlando P. da Silva
From the Departments of *Pediatrics, †Pharmacy and ‡Nursing, University of Western Ontario and St. Joseph's Health Care London, London, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David C. Knoppert
From the Departments of *Pediatrics, †Pharmacy and ‡Nursing, University of Western Ontario and St. Joseph's Health Care London, London, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle M. Angelini
From the Departments of *Pediatrics, †Pharmacy and ‡Nursing, University of Western Ontario and St. Joseph's Health Care London, London, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Penelope A. Forret
From the Departments of *Pediatrics, †Pharmacy and ‡Nursing, University of Western Ontario and St. Joseph's Health Care London, London, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Abstract

Background: Varying degrees of success have been reported with strategies to increase milk production when lactation is failing. The objective of this study was to investigate the efficacy of domperidone in augmenting milk production in mothers of premature newborns.

Methods: Twenty patients were randomly assigned to receive either domperidone or placebo for 7 days. Milk volume was measured daily. Domperidone levels were measured in randomly selected milk and serum samples on day 5 of the study. Serum prolactin levels were measured before the start of the study, on day 5 and on day 10 (3 days after the last dose of the study medication).

Results: Data from 16 patients were available for analysis (7 in the domperidone group and 9 in the placebo group). When compared with baseline values, the mean increase in the volume of milk production from day 2 to 7 was 49.5 (standard deviation [SD] 29.4) mL in the domperidone group and 8.0 (SD 39.5) mL in the placebo group (p < 0.05); proportionally this represented an increase of 44.5% and 16.6% respectively. The serum prolactin levels were similar in the 2 groups at baseline; by day 5 they were significantly higher in the domperidone group than in the placebo group, returning to baseline levels in both groups 3 days after the last dose of the study medication. Very small amounts of domperidone were detected in the breast milk samples.

Interpretation: In the short term domperidone increases milk production in women with low milk supply and is detected at low levels in breast milk.

Breastfeeding is recommended as the optimal form of nutrition for term and premature infants.1,2 There are several advantages to breastfeeding, including the psychological benefits of maternal–infant bonding, gastrointestinal trophic aspects and anti-infective benefits for the infant.1,2,3,4,5,6,7,8,9,10 In addition, there is some evidence that the use of human milk may be associated with long-term benefits for intellectual development even when used for a short period.11,12,13 When direct breastfeeding is not possible, the use of expressed mother's milk, fortified when necessary, is recommended to achieve the high nutrient demands of the very-low-birth-weight infant.1,2,3,4,5 However, mothers who wish to express milk for their hospitalized premature newborns are faced with numerous stressful situations. The often unstable clinical condition of the infant combined with concerns about prognosis and survival, and the distance from home, frequently have a detrimental effect on milk supply.

Varying degrees of success have been reported with strategies to increase milk production when lactation is failing, including support, relaxation techniques, mechanical expression and drug therapy.14,15,16,17 Of all the pharmacological interventions to augment lactation, metoclopramide, a central dopamine antagonist, has been the most widely studied.15,18,19,20,21 However, it crosses the blood–brain barrier, is secreted in significant amounts in breast milk17,22,23,24 and has been reported to affect dopamine-mediated responses in offspring of nursing rats.25

Domperidone is a peripheral dopamine antagonist that is indicated for use as an upper gastrointestinal motility modifier.26 Unlike metoclopramide, it does not readily cross the blood–brain barrier.26,27,28 >Preliminary data suggest that domperidone may be useful in augmenting milk production in women with insufficient lactation.29,30 >However, these studies had several methodological shortcomings, including inappropriate control groups and no information on the blinding of subjects or the method of randomization, and in both studies the infants were weighed before and after breastfeeding, an unreliable method at best.

We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy of domperidone in augmenting lactation in mothers of premature infants. Secondary objectives included the determination of serum prolactin levels in response to orally administered domperidone and of domperidone levels in serum and breast milk.

Methods

The study design was approved by the University of Western Ontario Ethics Committee on Research Involving Human Subjects and the Hospital Clinical Research and Pharmacy and Therapeutics Committees.

The study group included puerperal subjects who had their infants admitted to the neonatal intensive care unit at St. Joseph's Health Care London, in London, Ont. All mothers were mechanically expressing breast milk to be fed to their infants through a nasogastric tube. The women were assessed by our team of lactation consultants and extensively counselled before entering the study. If the milk production remained low (did not meet the infant's daily oral feeding requirements) mothers were informed about our study. They were eligible to participate if they were using an electric breast pump with a double collection kit, were not receiving any medication known to affect serum prolactin levels and did not have a chronic or debilitating illness.

After informed consent was obtained, mothers were randomly assigned to receive either domperidone (10 mg orally 3 times daily) or placebo for 7 days. Domperidone tablets were crushed and mixed with lactose. The resulting powder was placed in clear capsules, as was plain lactose powder, which acted as the placebo.

Breast milk was collected using the Lactinadouble breast pump (Medela Canada, Mississauga, Ont.). Each subject received an ample supply of collection bottles. These one-time use sterile containers accurately measure the volume of milk to the millilitre. The women were instructed to use a new container for each pumping and not to add milk together from 2 different pumpings. They were given recording sheets and adhesive labels to record the amount of milk collected, the date and the time. Milk volume was measured daily. A small amount of milk was retained from all patients on study day 5 for the measurement of domperidone concentrations. The mothers were instructed to record any side effects during treatment, particularly dry mouth, headache, insomnia, abdominal cramps, diarrhea, nausea and urinary retention. The record was reviewed with each woman on day 5 and on day 10 (3 days after the last dose of the study medication), at the time of the visit for blood sampling.

Three blood samples were obtained from each patient to determine serum domperidone and prolactin concentrations before the initial dose, on day 5 and on day 10. All serum and milk samples were kept frozen at –20oC for later analysis. Serum prolactin concentrations were determined using the IMx prolactin assay (Abbott Laboratories, Abbott Park, Ill.), a microparticle enzyme immunoassay. The analyzer used was an Abbott IMx Automated Immunoassay Analyzer. Domperidone concentrations were determined by means of isocratic reversed-phase high-performance liquid chromatography with mass selective detection.31

We calculated that 20 subjects would need to be enrolled to demonstrate an increase of at least 25% in milk production (considered clinically significant) from baseline in the study group compared with the placebo group at a power of 80% and an αlevel of 0.05. Categorical data between the 2 groups were compared with the 𝛘2 test, and continuous data were compared with Student's t-test. The mean increase in the volume of milk from baseline in the 2 groups was compared with the Wilcoxon rank sum test. Simple randomization was achieved using a random numbers table, and patient allocation was carried out in the hospital pharmacy using opaque sealed envelopes. Neither the patients nor the practitioners knew the treatment assignment.

Results

Of the 23 eligible women 20 agreed to participate in the study (Fig. 1). Four of the 20 women were excluded from the final analysis: no milk records were returned in 3 cases, and in 1 case the infant died of neonatal complications shortly after enrolment. The mean maternal age, gestational age at delivery, post-delivery day at study entry, parity, smoking habits, reasons for preterm delivery and previous breast-feeding experience were similar in the 2 groups (Table 1).

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Fig. 1: Profile of trial. R = randomization.

The baseline milk production (the volume produced in the 24 hours before the start of the study medication) was not available for 4 of the remaining 16 subjects (3 in the placebo group and 1 in the domperidone group); the volume of milk produced in the 24 hours following enrolment was taken as the baseline in these cases. The mean volume of milk at baseline was 112.8 (standard deviation [SD] 128.7) mL in the domperidone group and 48.2 (SD 63.3) mL in the placebo group. The mean daily volume of milk collected during study days 2 to 7 was 162.2 (SD 127.5) mL in the domperidone group and 56.1 (SD 48.0) mL in the placebo group. Compared with baseline values the mean increase was significantly greater in the domperidone group than in the placebo group (49.5 [SD 29.4] mL versus 8.0 [SD 39.5] mL respectively, p < 0.05). Proportionally this represented an increase from baseline of 44.5% and 16.6% respectively. The daily milk records for each patient are shown in Table 2.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 2.

At baseline the mean serum prolactin levels were similar in the domperidone and placebo groups (12.9 [SD 7.7] μg/L and 15.6 [SD 17] μg/L respectively, p = 0.70). By day 5 there was a significantly greater increase in the serum prolactin levels in the domperidone group than in the placebo group (119.3 [SD 97.3] μg/L v. 18.1 [SD 14.7] μg/L, p = 0.008). These values returned to baseline levels by day 10 (3 days after the last dose of the study medication): 12.1 (SD 5.1) μg/L in the domperidone group and 16.5 (SD 5.2) μg/L in the control group (p = 0.11).

On day 5, subjects in the treatment group had a mean domperidone concentration (as measured in randomly selected serum and milk samples) of 6.6 (SD 5.7) ng/mL in serum (n = 6) and 1.2 (SD 0.6) ng/mL in breast milk (n = 6). The serum and milk domperidone levels in the placebo group were below the limit of detection of the assay used.

Compliance was monitored by capsule count. All subjects complied with the assigned treatment group. In one instance a subject assigned to the domperidone group stopped taking the drug on day 4 of the study because she started to breastfeed her infant successfully. One woman in the placebo group failed to return milk records during the latter part of the study period. Data on these patients were included in the final analysis. No side effects were reported during the study. No obvious adverse effects were identified after reviewing the infants' records. The proportion of infants discharged home who were breastfeeding did not differ between the 2 groups.

Interpretation

There is a paucity of information in the literature regarding the role of domperidone as a galactagogue. Given the importance of breast milk in the feeding of newborns, every effort should be made to enhance breast milk production in lactating mothers of infants admitted to a neonatal intensive care unit. These mothers are usually faced with many barriers to initiating and sustaining lactation given the baby's critical clinical condition and the limitations of breast pumping in the long term. Our study has shown that domperidone is a safe and effective medication in the short term.

Because the infants in our study were not yet nursing we could accurately measure the milk volume collected on a daily basis. Women in the domperidone group experienced a steady increase in milk volume, starting 48 hours after initiation of the medication and continuing gradually up to the last day of treatment. We could not correlate this steady increase in milk volume with the raise in hormone levels, because the serum prolactin level was measured only 3 times during the study period.

How domperidone increases milk production is not well understood. It is hypothesized that the drug stimulates prolactin secretion.24,29 Our results support this hypothesis: we found a significantly greater rise in the serum prolactin levels in the domperidone group than in the placebo group.

Very small concentrations of domperidone were found in the breast milk samples randomly selected on day 5; this finding is in keeping with the findings of other investigators.23,24 The milk:serum ratio in our study (0.4) is within the range reported for a small number of women in an earlier study.24 This relatively low value is likely related to domperidone's high protein binding (greater than 90%)32 and to its relatively high molecular weight. The amount of domperidone that would be ingested by the infant would be extremely small (less than 0.2 μg/kg daily, assuming a daily milk intake of 150 mL/kg and a milk domperidone concentration of 1.2 ng/mL found in this study). This amount is much lower than the level of metoclopramide (approximately 125 ng/mL) that has been measured in the breast milk of nursing mothers treated with this drug.23,24 Upon reviewing the infants' charts, we found no reported side effects attributable to domperidone.

Milk production at baseline was higher in the domperidone group than in the placebo group. One possible explanation could be that 3 patients in the domperidone group had delivered multiples (2 sets of triplets and 1 set of twins), as compared with only one set of multiples in the placebo group. Proportionally these patients did not experience a greater response to domperidone than the ones with a lower milk output. The relatively long delay between delivery and study entry is explained by the fact that all women failing lactation in our centre received extensive teaching by our team of lactation consultants. The majority of women responded favourably with improvement in milk production. The women who continued to have problems with lactation after the teaching were eligible to enter the study.

We did not evaluate long-term milk production because most of the women initiated some level of breastfeeding soon after the end of the 7-day trial, and it was not practical to measure milk volume beyond the study period. Therefore we were unable to determine whether the increase in milk volume with domperidone was sustained.

Many questions need to be answered before domperidone can be routinely recommended to increase lactation. In particular, it is not known whether the short-term benefit of domperidone will be sustained. Also, the long-term effects of this drug on the infant, if any, need to be determined. A large multicentre trial should be conducted to address these questions.

Acknowledgments

We thank Courtney MacDonald for performing the domperidone assays and Janssen Pharmaceutica for supplying the pure domperidone samples for the assay.

This study was funded by a grant from the Research and Education Foundation of the Canadian Society of Hospital Pharmacists.

Footnotes

  • This article has been peer reviewed.

    Contributors: Orlando da Silva co-wrote the protocol, coordinated the study, managed the data, and contributed to and coordinated the writing and revision of the manuscript. David Knoppert co-wrote the protocol, conducted the randomization, dispensed the study drug and contributed to the writing and revision of the manuscript. Michelle Angelini and Penelope Forret contributed to the writing of the protocol, recruited patients, counselled mothers with breast-feeding techniques, took blood samples for analysis, collected the clinical data and contributed to the writing of the manuscript.

    Competing interests: None declared.

    Reprint requests to: Dr. Orlando P. da Silva, Department of Pediatrics, St. Joseph's Health Care London, 268 Grosvenor St., London ON N6A 4V2; fax 519 646-6123; odasilva@julian.uwo.ca

References

  1. 1.↵
    American Academy of Pediatrics, Work Group on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 1997;100:1035-9.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Canadian Paediatric Society clinical practice guideline: nutrition for healthy term infants. Paediatr Child Health 1998;3:109-12.
    OpenUrlPubMed
  3. 3.↵
    Schanler RJ, Hurst NM. Human milk for the hospitalized preterm infant. Semin Perinatol 1994;18:476-86.
    OpenUrlPubMed
  4. 4.↵
    Schanler RJ, Shulman RJ, Lau C. Feeding strategies for premature infants: beneficial outcomes of feeding fortified human milk versus preterm formula. Pediatrics 1999;103:1150-7.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Nutrition Committee, Canadian Paediatric Society. Nutrient needs and feeding of premature infants. CMAJ 1995;152(11):1765-84. Available: www.cps.ca/english/statements/N/n95-01.htm
    OpenUrlAbstract
  6. 6.↵
    Tudehope DI, Steer PA. Which milk for preterm infant? J Paediatr Child Health 1996;32:275-7.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Ogra PL, Rassin DK. Human breast milk. In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infant. 4th ed. Philadelphia: WB Saunders; 1995. p. 108-39.
  8. 8.↵
    Delneri MT, Carbone SB, Silva ML, Palmeira P, Carneiro-Sampaio MM. Inhibition of enteropathogenic Escherichia coli adhesion to HEp-2 cells by colostrum and milk from mothers delivering low-birth-weight neonates. Eur J Pediatr 1997;156:493-8.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Scariati PD, Grummer-Strawn LM, Fein SB. A longitudinal analysis of infant morbidity and the extent of breastfeeding in the United States. Pediatrics 1997;99(6):E5.
  10. 10.↵
    Hylander MA, Strobino DM, Dhanireddy R. Human milk feedings and infection among very low birth weight infants. Pediatrics 1998;102(3):E38.
  11. 11.↵
    Morley R. The influence of early diet on later development. J Biosoc Sci 1996;28:481-7.
    OpenUrlPubMed
  12. 12.↵
    Lucas A, Morley R, Cole TJ, et al. Early diet in preterm babies and development status at 18 months. Lancet 1990;335:1477-81.
    OpenUrlCrossRefPubMed
  13. 13.↵
    Lucas A, Morley R, Cole TJ, Lister G, Leeson-Payne C. Breast milk and subsequent intelligence quotient in children born preterm. Lancet 1992;339:261-4.
    OpenUrlCrossRefPubMed
  14. 14.↵
    Feher SDK, Berger LR, Johnson JD, Wilde JB. Increasing breast milk production for premature infants with a relaxation/imagery audiotape. Pediatrics 1989;83:57-60.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Emery MM. Galactogogues: drugs to induce lactation. J Hum Lact 1996;12:55-7.
    OpenUrlFREE Full Text
  16. 16.↵
    Hill PD, Aldag JC, Chatterton RT. The effect of sequential and simultaneous breast pumping on milk volume and prolactin levels: a pilot study. J Hum Lact 1996;12:193-9.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Lewis PJ, Devenish C, Kahn C. Controlled trial of metoclopramide in the initiation of breast feeding. Br J Clin Pharmacol 1980;9:217-19.
    OpenUrlCrossRefPubMed
  18. 18.↵
    Ehrenkranz RA, Ackerman BA. Metoclopramide effect on faltering milk production by mothers of premature infants. Pediatrics 1986;78:614-20.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    Kauppila A, Kivinen S, Ylikorkala O. A dose response relation between improved lactation and metoclopramide. Lancet 1981;1:1175-7.
    OpenUrlPubMed
  20. 20.↵
    Budd SC, Erdman SH, Long DM, Trombley SK, Udall JN. Improved lactation with metoclopramide. Clin Pediatr 1993;35:53-7.
    OpenUrl
  21. 21.↵
    Gupta AP, Gupta PK. Metoclopramide as a lactogogue. Clin Pediatr 1985;24: 269-72.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    Kauppila A, Arvela P, Koivisto M, Kiniven S, Ylikorkala O, Pelkonen O. Metoclopramide and breast feeding: transfer into milk and the newborn. Eur J Clin Pharmacol 1983;25:819-23.
    OpenUrlCrossRefPubMed
  23. 23.↵
    Hofmeyr GJ, Van Iddekinge B. Domperidone and lactation. Lancet 1983;1:647.
    OpenUrlPubMed
  24. 24.↵
    Hofmeyr GJ, Van Iddekinge B, Blott JA. Domperidone: secretion in breast milk and effect on puerperal prolactin levels. Br J Obstet Gynaecol 1985;92:141-4.
    OpenUrlCrossRefPubMed
  25. 25.↵
    Engel JA, Lundborg P. Behavioral and biochemical effects in offspring of nursing rats exposed to dopamine receptor antagonists. In vol 1 of 13th Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 1982 June 22; Jerusalem. Abstract 198.
  26. 26.↵
    Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone: a review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 1982;24:360-400.
    OpenUrlCrossRefPubMed
  27. 27.↵
    Cann PA, Read NW, Holdsworth CD. Galactorrhoea as a side effect of domperidone [letter]. BMJ 1983;286:1395-6.
    OpenUrlFREE Full Text
  28. 28.↵
    Brouwers JR, Assies J, Wiersinga WM, Huizing G, Tytgat GN. Plasma prolactin levels after acute and subchronic oral administration of domperidone and metoclopramide: a cross-over study in healthy volunteers. Clin Endocrinol (Oxf) 1980;12:435-40.
  29. 29.↵
    Petraglia F, De leo V, Sardelli S, Pieroni ML, D'Antona N, Genazzani AR. Domperidone in defective and insufficient lactation. Eur J Obstet Gynecol Reprod Biol 1985;19:281-7.
    OpenUrlCrossRefPubMed
  30. 30.↵
    Rolfini G, De Rosa D, Lupi AM, Petrelli V. [Hypogalactia: therapeutic possibilities] [Italian]. Clin Ter 1989;129:185-91.
    OpenUrlPubMed
  31. 31.↵
    Zavitsanos AP, MacDonald C, Bassoo E, Gopaul D. Determination of domperidone in human serum and human milk by high-performance liquid chromatography-electrospray mass spectrometry. J Chromatogr B 1999;730:9-24.
    OpenUrlCrossRef
  32. 32.↵
    Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man. IV: the pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 1981;6:61-70.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

CMAJ
Vol. 164, Issue 1
9 Jan 2001
  • Table of Contents
  • Index by author
  • Canadian Adverse Drug Reaction Newsletter (91-98)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial
Orlando P. da Silva, David C. Knoppert, Michelle M. Angelini, Penelope A. Forret
CMAJ Jan 2001, 164 (1) 17-21;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial
Orlando P. da Silva, David C. Knoppert, Michelle M. Angelini, Penelope A. Forret
CMAJ Jan 2001, 164 (1) 17-21;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Interpretation
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Analysis of the association between rs111200466 variants and cervical Cancer susceptibility in Sudanese women
  • Efficacy of Wang Nam Yen herbal tea on human milk production: A randomized controlled trial
  • A Review of Herbal and Pharmaceutical Galactagogues for Breast-Feeding
  • Postpartum domperidone use in British Columbia: a retrospective cohort study
  • Feeding infants directly at the breast during the postpartum hospital stay is associated with increased breastfeeding at 6 months postpartum: a prospective cohort study
  • Health Canada advisory on domperidone: Should I avoid prescribing domperidone to women to increase milk production?
  • Metoclopramide or domperidone for increasing maternal breast milk output: a randomised controlled trial
  • Effect of Domperidone on the Composition of Preterm Human Breast Milk
  • Evidence-based Practices to Promote Exclusive Feeding of Human Milk in Very Low-birthweight Infants
  • Optimising the provision of human milk for preterm infants
  • Breast feeding twins and high multiples.
  • Nursing the Adopted Infant
  • Randomised, double blind trial of oxytocin nasal spray in mothers expressing breast milk for preterm infants
  • Domperidone for lactating women
  • Google Scholar

More in this TOC Section

  • Falsely elevated point-of-care lactate measurement after ingestion of ethylene glycol
  • Severe necrotizing pancreatitis following combined hepatitis A and B vaccination
  • Can hockey playoffs harm your hearing?
Show more Research article

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire